Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24
1999
Chromosome 17q Gain and Neuroblastoma Prognosis
Sample size: 48
publication
Evidence: moderate
Author Information
Author(s): Abel F, Ejeskär K, Kogner P, Martinsson T
Primary Institution: Sahlgrenska University Hospital/East, Gothenburg, Sweden
Hypothesis
Is gain of chromosome arm 17q associated with prognosis in neuroblastoma?
Conclusion
Gain of chromosome arm 17q is a common genetic alteration in neuroblastoma and is linked to poor prognosis.
Supporting Evidence
- 31 of the 48 neuroblastomas (65%) showed 17q gain, significantly associated with poor prognosis.
- 17q gain was significantly associated with metastatic stage 4 neuroblastoma.
- Children with no 17q gain had a 5-year survival probability of 100%, compared to 52.5% for those with 17q gain.
Takeaway
This study found that having extra genetic material on chromosome 17q makes it more likely for kids with neuroblastoma to have a worse outcome.
Methodology
Fluorescence in situ hybridization (FISH) was used to analyze 17q status in neuroblastoma tumors, and mutation screening of the SSTR2 gene was performed using polymerase chain reaction-based methods.
Statistical Information
P-Value
0.0009
Statistical Significance
p=0.0009
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website